Audit: QRS - Chromium for Health & Longevity

Audit conducted on 11/09/2026 08:45 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	81
Failed	0
N/A	12
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Spot-checked every populated span against the ER: protocol cells vs ER L363/L373/L377, time cells vs ER L420/L356, benefit and risk tiers vs ER headings, all 11 markers vs ER table L452-462, cadence vs ER L448.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Hedges carried over: “Where present”, “no comparative trial exists”, “no trial has compared morning against evening administration”, “small pooled effect claimed”, “No target; track change from own baseline”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindication thresholds and the “unless the clinician adjusts the regimen first” condition are preserved at ER strength.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications and Key Interactions both come from the ER Key Interactions & Contraindications section; no Benefit- or Risk-Modifying Factor is recategorised.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT identifiers, expert names or brands appear. Generic drug names in the gates all come from the matching ER interaction bullets.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind appear in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Conditional, sceptical framing of the ER is preserved, including the population-dependence of benefit.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Tiered benefits and risks plus quantified marker targets keep the sheet data-driven while remaining readable.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Statements are descriptive throughout; no directive voice.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Content is presented as evidence; the footer disclaimer is the template’s fixed text.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommend”, “advise” or “you should” constructions anywhere in the sheet.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person address; verified no occurrence of “you” or “your”.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Plain language throughout; marker acronyms are confined to the Monitoring table where they are the standard assay names.
2.8	Information is presented in a concise and very compact manner	🟢	Every populated span is a condensed fragment; no prose paragraphs beyond the 58-word lede.
2.9	It DOES NOT address the reader directly	🟢	Verified no second-person pronouns in the source.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	The lede leads with the fact that benefit is confined to impaired glucose control, which is the decision the target audience faces.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Protocol, time-boxed course and an 11-marker monitoring panel assume a reader willing to test and track.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	The sheet assumes laboratory testing and dose titration, well beyond general-population framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The lede explicitly surfaces the adverse insulin-sensitivity signal in metabolically healthy adults, the signal specific to this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The term “anti-aging” does not occur.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Register is clinical throughout; no “pill”, “shot”, “taken by mouth” or similar consumer phrasing.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate headings, tier labels and the Marker/Target/Why column headers match the template exactly.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 38 template spans are present; the marker_#_* and qualitative_item_# patterns are instantiated as marker_1-11 and qualitative_item_1-6.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A scaffold diff against the template shows no change outside the variable spans and the metadata block; the three website= spans are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section that the QRS draws on is empty, so no empty-state phrasing applies.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels “Standard dose range”, “Best time of day” and “Single versus split dosing” are the ER’s bold labels verbatim; marker names match the ER table rows verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Time-to-effect labels use the ER’s own wording (“Glucose endpoints”, “Weight and appetite” from ER L420).
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No 🟩, 🟥, 🟨 or ⚠️ characters occur; the ER’s “Conflicted” markers were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed rather than expanded: 58-word lede, tier lines collapsed to semicolon-separated fragments, gate items stripped to the key fact, marker rationales reduced to one clause.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	The metadata comment spans lines 2-14, immediately after <!doctype html> and before <html>.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opened at line 3 and closed at line 13; the descriptive text on line 2 sits outside the YAML.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	The block is an HTML comment and no element on the sheet reproduces it.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:04" is quoted, which is required because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: chromium_2026-0911-0550_Opus_ER.md
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02, matching the version badge at the top of QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0911-0829.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version number with no trailing qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: chromium_2026-0911-0550_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified: all values trimmed, single quoted value justified by its colon.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Chromium for Health & Longevity - Quick Reference Sheet”, with the ampersand entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“Chromium for Health & Longevity”, matching the ER canonical_topic.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	09/11/2026, the MM/DD/YYYY form of qrs_creation_date 2026-0911-0829.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5”, matching qrs_creator_ai_fullname.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header carries only the title and the template subline; no badge, AKA line or audit stamp.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses the ER Conclusion (L495-499) into the population split, the adverse signal, the harm profile and the contamination gap.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each of the four claims maps to a distinct ER Conclusion passage (L495 twice, L497 twice).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “blood sugar control” and “how the body handles sugar” replace the technical register.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No study name, year or sample size; the adverse signal is attributed only as “one study”.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No effect sizes, risk ratios or statistics.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Taken from the ER’s “Populations who should avoid Chromium” list at ER L335-341.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All five ER avoidance populations are represented, one <li> each.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Five well-formed <li> elements inside the [stop_items] span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Trailing rationale is stripped, e.g. the ER’s “where supplemental safety is unstudied” on the pregnancy item; no dash-led clauses remain.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Thresholds retained: 45 mL/min/1.73 m², Child-Pugh Class B or C, 3x upper limit, 29-30 and 44-45 µg/day.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s contraindication bullets use no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	N/A	The section is not empty; five contraindication items are present.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty, so no explanatory HTML comment is required.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Taken from the ER’s ten interaction bullets at ER L315-333.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All ten ER interactions are present and none duplicates a contraindication entry.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Ten well-formed <li> elements inside the [caution_items] span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Severity, consequence and mitigation clauses are stripped from every bullet; only the agent or class remains.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every example drug list is preserved verbatim, including the six-item supplement list and the three-item other-interventions list.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction bullets use no ranking notation inside parentheses.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	N/A	The section is not empty; ten interaction items are present.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty, so no explanatory HTML comment is required.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Derived from the ER Therapeutic Protocol section (ER L361-387).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose range, timing and single-versus-split dosing are the three actionable dimensions of the ER protocol; the remaining bullets are context rather than actions.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct actionable implementation aspects are present; no unused sets.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine action spans carry ER-derived content (ER L363, L373, L377).

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Glucose endpoints and weight/appetite come from ER L420; the time-boxed course window comes from ER L356/L392.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered High-tier benefit (glycemic control) first, Medium-tier (weight and appetite) second, with the overall course window last.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time-to-effect aspects are present; no unused sets.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine time spans carry ER-derived content.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect data, so the row is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Derived from the ER Expected Benefits section (ER L151-219).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four tier spans are populated.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Evidence-strength qualifiers “Modest” and “Small” are dropped and each ER heading is reduced to its key fact; the population scope that defines each benefit is retained.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content survives; the ER’s inline glosses for HDL, LDL and polycystic ovary syndrome are not carried over.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers carry items; no span needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Derived from the ER Potential Risks & Side Effects section (ER L241-291).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four tier spans are populated.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each ER risk heading is reduced to its key fact with no mechanism or frequency.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content survives; the ER’s glosses for hemolysis, thrombocytopenia and rhabdomyolysis are not carried over.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers carry items; no span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Derived from the ER Monitoring Protocol & Defining Success table (ER L450-462).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 11 ER biomarkers are listed in ER order, with targets matching the ER’s optimal functional ranges exactly.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Populated with the cadence from ER L448: fasting baseline, 12-week repeats, 6-12 month kidney and liver follow-up, annual full panel.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Derived from the qualitative marker list in the ER Monitoring Protocol & Defining Success section (ER L466-471).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers are listed verbatim.

Issues 11/09/2026 08:45

Pass rate 100.00%. No issues found.

Issues 11/09/2026 08:39

1. 4.5 — Monitoring section not condensed: The Monitoring card transfers the ER biomarker table’s Why column verbatim (QRS lines 647-792), leaving 9 of 11 entries at 64-91 characters so each row wraps to two lines; together with the 218-character cadence line (lines 799-803) and the 70-character marker_11_target (lines 784-786) this pushes the sheet well past the one-A4-page budget with no per-section condensation applied.

Fixes 11/09/2026 08:39

1. 4.5 — Monitoring Why column condensed: Shortened nine of the eleven marker_#_why entries so every row now fits a single rendered line (e.g. “Detects the insulin-sensitivity change that underlies any glucose effect” → “Insulin-sensitivity change underlying any glucose effect”), removing roughly eleven wrapped lines from the Monitoring card.

2. 4.5 — Chromium exposure target shortened: Reduced marker_11_target from “No established target; track change from the individual’s own baseline” to “No target; track change from own baseline”, cutting that row from three lines to two.

3. 4.5 — Monitoring cadence tightened: Condensed monitoring_cadence from 218 to 148 characters, dropping “before the first dose”, “measures”, “panels” and “for anyone continuing beyond a single course” in favour of “if continuing”, while keeping the 12-week, 6–12-month and annual intervals intact.